Skip to main content

Rezolute, Inc.

corporate_fare Company Profile

Rezolute, Inc.

RZLT·NASDAQ·Life Sciences·CIK 0001509261

Rezolute, Inc. is a late-stage rare disease company that develops treatments for persistent and severe low blood sugar (hypoglycemia) linked to various forms of hyperinsulinism (HI). The company's primary clinical asset is ersodetug, an intravenously administered human monoclonal antibody. Ersodetug is designed to treat refractory hypoglycemia caused by multiple forms of hyperinsulinism. It works by binding to a specific site on the insulin receptor in insulin-sensitive tissues like the liver, fat, and muscle. This action reduces insulin receptor activity, which helps to normalize glucose levels in conditions where insulin or insulin-like substances (such as IGF-2 variants) are elevated. Ersodetug exhibits dose-dependent pharmacokinetics with a half-life exceeding 2 weeks, suggesting the potential for monthly dosing. The company is developing ersodetug to treat any form of HI, as its mechanism of action, downstream from the source of HI (insulin or IGF-2 production), could make it broadly effective for HI-related hypoglycemia, whether genetic or acquired. In the sunRIZE Phase 3 study for congenital HI, announced on December 11, 2025, ersodetug did not meet its primary endpoint (hypoglycemia events by finger stick self-monitored blood glucose) or its key secondary endpoint (time in hypoglycemia by continuous glucose monitoring) at the Week 24 evaluable window. However, the study consistently showed larger and often nominally statistically significant reductions in hypoglycemia compared to placebo throughout the maintenance dosing phase across various pre-specified and post-hoc CGM-based endpoints.

Rezolute, Inc. (NASDAQ:RZLT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for RZLT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • FDA Encourages Rezolute to Submit Full Data for Failed Phase 3 Drug, Offering Path Forward
  • Rezolute Reports Wider Net Loss and Increased Burn, Pivots Key Trial Design After sunRIZE Failure
  • Rezolute Reports Increased Loss, Significant Cash Burn, and Provides Update on Clinical Programs
  • Rezolute's Phase 3 sunRIZE Study Misses Primary Endpoints for Congenital HI; Tumor HI EAP Shows Strong Positive Results

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-$77.59M
Diluted EPS
-$0.75
Op. Cash Flow
-$64.64M
Operating Income
-$82.97M
Cash & Equivalents
$10.62M
Debt / Equity
0.00×
Shares Outstanding
96.41M sh
Source: 10-K · filed 2026-09-24 · accession 0001104659-26-110420
$3.95 +0.77% today
52-week range · as of 2026-11-13 $1.07 – $11.16
Market cap
$379.18M
Volume
2.5M (1.4× avg)
3-mo avg 1.7M
Live data · 2026-11-22 04:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RZLT - Filings & News (Page 2)

RZLT
Mar 24, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $3.95 info
Change: +$1.60 (+68%) info
Market Cap: $379.177M info
RZLT
Feb 12, 2026, 4:36 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.59
Real-time Price: $3.95 info
Change: +$0.359 (+10%) info
Market Cap: $379.177M info
RZLT
Feb 12, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.58
Real-time Price: $3.95 info
Change: +$0.370 (+10%) info
Market Cap: $379.177M info
RZLT
Jan 07, 2026, 6:10 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $3.95 info
Change: +$1.97 (+99%) info
Market Cap: $379.177M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets